Preliminary data showed that the two different erdosteine treatment groups did not seem to break statistically from placebo. The company said that further analyses will continue during the remainder of fiscal 2007 to determine the ultimate outcome of the study.
Adams Respiratory also said that trade orders have been disappointing due to a sharp decline in the reported levels of upper respiratory illness. CEO and president, Michael Valentino, said: “Unfortunately, we do not control the severity of the season or the purchasing decisions of our trade customers. By all accounts, our brands’ performance in the market has been strong. We hope to leverage our enhanced leadership position in the marketplace as we plan to introduce a new portfolio of OTC products next season.”